905 filings
Page 2 of 46
6-K
ujrwnkt2w l9klm8
1 Feb 23
Novartis continues to grow with further core margin expansion and achieves important innovation milestones
7:53am
6-K
2w2 5b7e19o75aj8u5d5
5 Dec 22
Current report (foreign)
9:27am
6-K
qsc19fbnn6rvrl gw
25 Oct 22
Current report (foreign)
9:40am
6-K
q1dqwuw76
24 Oct 22
Current report (foreign)
6:05am
6-K
3kgm acn4wy90ykp1
21 Sep 22
Current report (foreign)
6:05am
6-K
1kv1nhuwr yr6cj
25 Aug 22
Current report (foreign)
8:58am
6-K
xifxa
19 Jul 22
Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance
6:49am
6-K
hxmr48f
21 Jun 22
Current report (foreign)
4:21pm
6-K
6i75k68ndqk vyc1f
26 Apr 22
Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook
9:04am
6-K
k9ddgma
4 Apr 22
Current report (foreign)
6:08am
6-K
g6vtzwq
23 Mar 22
Current report (foreign)
7:48pm
6-K
qgewis3vjc 6lc0cfa7
2 Feb 22
Financial Results | Résultats Financiers | Finanzergebnisse
7:28am
6-K
y6vc2hz 9vcjkn
22 Dec 21
Current report (foreign)
4:41pm
6-K
esbx q2ktcvtbt
20 Dec 21
Current report (foreign)
6:05am
6-K
sxjeemmm
17 Dec 21
Current report (foreign)
8:07am
6-K
laoc6suh q9zeou64
4 Nov 21
Current report (foreign)
6:43am
6-K
n80jr8oqi
26 Oct 21
Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz
9:39am
6-K
a7h2cq
25 Oct 21
Current report (foreign)
6:05am
6-K
omq0mzru9
3 Aug 21
Current report (foreign)
6:30am
6-K
xrf0vrznp
21 Jul 21
Financial Results | Résultats Financiers | Finanzergebnisse
6:55am